Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650244 | 1.00 | HTR2C (0.42) | HTR2CSLC6A4KDM4EALDH1A1GAA | |
| SCHEMBL25702072 | 0.89 | APP (0.39) | KDM4EALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL21353203 | 0.84 | PTGDR2 (0.39) | KDM4EALDH1A1SMN1; SMN2GCKSCN9A | |
| SCHEMBL30199691 | 0.82 | TSHR (0.41) | KDM4EALDH1A1SMN1; SMN2GCKNPSR1 | |
| SCHEMBL29248231 | 0.76 | PTGDR2 (0.43) | KDM4EALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL25909811 | 0.74 | HSP90AA1 (0.41) | KDM4EALDH1A1METGRIN2BMEN1 | |
| SCHEMBL20483115 | 0.74 | KDM4E (0.39) | KDM4EALDH1A1METGRIN2B | |
| SCHEMBL25229548 | 0.73 | ALDH1A1 (0.41) | KDM4EALDH1A1METMAPTKMT2A | |
| SCHEMBL31194316 | 0.73 | MET (0.43) | KDM4EALDH1A1METGRIN2B | |
| SCHEMBL31194282 | 0.72 | GABRG2 (0.39) | KDM4EALDH1A1METGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111699189-B | Modulators of beta-3 adrenergic receptors useful for treating or preventing heart failure and disorders associated therewith | 艾尼纳制药公司 | 2025-02-18 | — | — | CN | disclosed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3464292-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-109563103-B | Modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11339172-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10927123-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3720858-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111699189-A | Modulators of beta-3 adrenergic receptors useful for the treatment or prevention of heart failure and disorders associated therewith | 艾尼纳制药公司 | 2020-09-22 | — | — | CN | disclosed |
| US-20200270264-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-10662200-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10479797-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190292196-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-19 | — | — | US | disclosed |
| WO-2019113359-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| CN-109563103-A | modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2019-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479797-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | HTR2C 734/4885SLC6A4 2023/4885KDM4E 4669/4885 |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | HTR2C 553/4885SLC6A4 1231/4885KDM4E 4728/4885 |
| US-20190292196-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | HTR2C 734/4885SLC6A4 2023/4885KDM4E 4669/4885 |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | HTR2C 734/4885SLC6A4 2023/4885KDM4E 4669/4885 |
| US-10927123-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | HTR2C 734/4885SLC6A4 2023/4885KDM4E 4669/4885 |
| US-10662200-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | HTR2C 734/4885SLC6A4 2023/4885KDM4E 4669/4885 |
| US-20200270264-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | HTR2C 734/4885SLC6A4 2023/4885KDM4E 4669/4885 |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | HTR2C 520/4885SLC6A4 1166/4885KDM4E 4739/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | HTR2C 520/4885SLC6A4 1166/4885KDM4E 4739/4885 |
| US-11339172-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | HTR2C 553/4885SLC6A4 1231/4885KDM4E 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.